We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
1Post Graduate Student, Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Kumarapalayam - 638183, Namakkal District, Tamil Nadu, India.
2,3Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Kumarapalayam - 638183, Namakkal District, Tamil Nadu, India.
Background: Chronic Obstructive Pulmonary Disease (COPD) is a significant global health problem. Long-acting muscarinic antagonists (LAMAs) such as glycopyrronium bromide and tiotropium bromide are key bronchodilators, however, comparative head to head clinical data on their therapeutic efficacy, pharmacokinetics, adverse drug reaction (ADR) rates and medication adherence remain limited.Objective/aims: To undertake systematic evaluation and comparison of the therapeutic efficacy, pharmacokinetics, adverse drug reaction rates and medication adherence of glycopyrronium vs. tiotropium and the additional impact on medication adherence of pharmacist counseling.Materials and Methods: The study enrolled 108 participants with Chronic Obstructive Pulmonary Disease who were assessed for efficacy using the CAT score and mMRC scale, for ADR via the Naranjo Scale and for medication adherence (MARS) and patient counseling using Patient Information Leaflets (PIL).Results: Glycopyrronium was associated with significant improvements in CAT scores (22.70 to 19.93) and mMRC grades (2.81 to 2.28) compared to tiotropium (CAT: 27.22 to 27.78; mMRC: 3.20 to 3.17). Glycopyrronium was associated with fewer adverse drug interactions (53.7% vs 70.4%) and higher medication adherence rates (81.5% vs 64.8%) compared to tiotropium. The most common anticholinergic ADR was dry mouth (42.6%). Clinical pharmacist counseling improved patient comprehension scores from 5.06 to 7.16.Conclusion: Glycopyrronium was overall safer and more effective than tiotropium with improved medication adherence rates. Clinical pharmacist counseling
1. Introduction & Pathophysiological Overview
Chronic Obstructive Pulmonary Disease (COPD) is a significant global health problem due to the progressive nature of the disease, structural airway remodeling and frequent exacerbations. The pathophysiology of COPD is multi-factorial with two key pathological processes contributing to airflow limitation:
1. Small airway disease/Obliterative bronchiolitis: Peribronchiolar fibrosis, goblet cell hyperplasia and hypertrophy of the bronchial smooth muscle and mucus secretion results in luminal narrowing.
2. Parenchymal destruction/Emphysema: Protease-antiprotease imbalance and oxidative stress leads to loss of elastic recoil of the alveolar walls.
Long-acting muscarinic antagonists (LAMAs), such as glycopyrronium bromide and tiotropium bromide, are key maintenance therapies in the treatment of COPD. Both work by competitive antagonism at muscarinic M3 receptors in the bronchial smooth muscle, resulting in bronchodilation. However, comparative head to head clinical data on the safety, real-world reduction of COPD symptom burden and medication adherence rates of glycopyrronium and tiotropium are limited.
2. Molecular Pharmacokinetics & Pharmacodynamics
Both glycopyrronium and tiotropium bromide are considered long-acting muscarinic antagonists (LAMAs) but differ considerably in their receptor pharmacology:
• Glycopyrronium Bromide: Glycopyrronium bromide is a synthetic quaternary ammonium compound formulated specifically for rapid binding to human M3 muscarinic receptors with rapid dissociation from presynaptic M2 autoreceptors. The short initial plasma half-life (~0.6–1.2 hours) minimizes systemic exposure, while the rapid onset of action (<5 minutes) provides immediate symptomatic relief.
• Tiotropium Bromide: Tiotropium bromide is a dithienylglycolate derivative that exhibits exceptionally long receptor occupancy through slow dissociation from M3 muscarinic receptors (t1/2 > 27 hours). While this results in sustained 24-hour bronchodilation, the delayed onset of maximal efficacy (30–45 minutes) and very long elimination half-life (5–6 days) may necessitate dose adjustments in elderly or renal impaired patients.
Table 1: Comparative Pharmacological & Kinetic Parameters
| Pharmacological / Kinetic Metric | Glycopyrronium Bromide | Tiotropium Bromide |
|---|---|---|
| Chemical Subclass | Synthetic Quaternary Ammonium | Dithienylglycolate Derivative |
| M3 Receptor Onset Speed | Rapid (< 5 minutes) | Moderate (30–45 minutes) |
| M3 Dissociation Half-Life | Long (~6.1 hours) | Extremely Long (> 27 hours) |
| Presynaptic M2 Dissociation | Rapid (Protective against feedback) | Moderate |
| Terminal Plasma Half-Life (t1/2) | Initial 0.6–1.2h; Terminal ~33h | Terminal 5–6 days |
3. Trial Methodology & Workflow Design
A prospective clinical assessment of 108 chronic obstructive pulmonary disease (COPD) participants was undertaken that incorporated four interconnected domains of evaluation: Efficacy (CAT & mMRC), Safety (Naranjo Scale), Adherence (MARS) and Counseling (PIL & Pre/Post Questionnaires).
Figure 1: Integrated Patient Flow & Assessment Protocol
| Phase 1: Baseline Assessment | Evaluation of 108 COPD participants. Baseline recording of CAT score (symptom burden), mMRC dyspnea grade, MARS questionnaire and initial disease comprehension. |
|---|---|
| Phase 2: Active LAMA Arm Allocation | Glycopyrronium Arm vs Tiotropium Arm. Longitudinal assessment of symptomatic changes, adverse drug reactions and drug interaction rates. |
| Phase 3: Pharmacist-Led Intervention | Structured counseling session using Patient Information Leaflets (PIL), device demonstration (MDI/DPI technique) and self-management education. |
| Phase 4: Post-Intervention Audit | Re-evaluation of CAT and mMRC scores, Naranjo causality scoring for ADRs, MARS compliance calculation, post-counseling knowledge scoring. |
4. Comparative Clinical Findings
The comparative clinical findings for glycopyrronium and tiotropium are summarized below.
Table 2: Head to Head Clinical Outcomes Summary
| Clinical Parameter / Metric | Glycopyrronium Cohort | Tiotropium Cohort | Statistical / Clinical Significance |
|---|---|---|---|
| Baseline CAT Score | 22.70 ± 3.12 | 27.22 ± 3.45 | Initial health impact score |
| Post-Treatment CAT Score | 19.93 ± 2.84 | 27.78 ± 3.60 | Glycopyrronium: -2.77 shift (> MCID threshold of 2.0) |
| Baseline mMRC Dyspnea Grade | 2.81 ± 0.45 | 3.20 ± 0.51 | Baseline functional breathlessness |
| Post-Treatment mMRC Grade | 2.28 ± 0.38 | 3.17 ± 0.48 | Glycopyrronium achieved greater dyspnea reduction (-0.53) |
| Overall Interaction Rate (%) | 53.7% | 70.4% | Significantly lower interaction frequency in glycopyrronium |
| Predominant Anticholinergic ADR | Dry Mouth (42.6%) | Dry Mouth (42.6%) | Shared M3 salivary blockade class effect |
| Medication Adherence (MARS) | 81.5% | 64.8% | Glycopyrronium group showed superior compliance |
| Pre-Counseling Knowledge Score | 5.06 ± 1.12 | 5.06 ± 1.12 | Pooled baseline patient comprehension |
| Post-Counseling Knowledge Score | 7.16 ± 0.94 | 7.16 ± 0.94 | Statistically significant improvement post-intervention |
DISCUSSION
5.1 Efficacy Dynamics & Symptom Control
The reduction in CAT score from 22.70 to 19.93 in the glycopyrronium arm exceeded the established Minimal Clinically Important Difference (MCID) threshold of 2.0 units, indicating clinically meaningful improvement in patients' health status. Similarly, the decrease in mMRC score from 2.81 to 2.28 demonstrated a measurable reduction in exertional dyspnea. Conversely, the patients receiving tiotropium exhibited minimal changes in mMRC scores (3.20 to 3.17) and a slight drift in CAT scores (27.22 to 27.78), which may reflect differences in baseline disease severity, device usability or variable inhalation technique.
5.2 Safety Profiles, Naranjo Assessment & Drug Interactions
A systematic analysis of adverse drug reactions (ADRs) using the Naranjo scale categorized the majority of the reported events as 'probable' or 'possible'. Dry mouth (xerostomia) was identified as the primary anticholinergic reaction in both arms (42.6%). However, glycopyrronium was associated with a lower overall interaction rate (53.7% vs 70.4%), which can be attributed to its faster systemic clearance and reduced potential for accumulation over time.
5.3 Medication Adherence & Inhaler Usability (MARS)
The improved medication adherence in the glycopyrronium arm (81.5% vs 64.8%) can be attributed to several factors: 1) The rapid onset of symptom relief within 5 minutes provides immediate positive feedback; 2) The low resistance capsule dry powder inhalers (e.g., Breezhaler) offer clear visual, auditory and sensory feedback during inhalation; and 3) The reduced number of systemic side effects minimize treatment disruptions.
5.4 Impact of Clinical Pharmacist Counseling
Structured pharmacist counseling incorporating Patient Information Leaflets (PIL) resulted in a significant increase in disease comprehension scores (from 5.06 to 7.16). Correction of common inhaler errors (e.g., inadequate exhalation, incorrect actuation-inhalation coordination) directly improves lung deposition and treatment outcomes.
CONCLUSION
This head to head study demonstrated that glycopyrronium provided superior clinical benefits compared to tiotropium in terms of symptom reduction (CAT and mMRC scores), safety profiles (lower drug interaction rates) and medication adherence (MARS). Furthermore, the involvement of clinical pharmacists in patient counseling significantly improved patient understanding and inhaler technique, emphasizing the importance of inter-professional pharmacy management in the treatment of COPD.
REFERENCES
Shafika Rishmana, Dr. Senthil M., Senthil Madasamy, Comparative Safety, Efficacy, Pharmacokinetics and Medication Adherence of Glycopyrronium vs. Tiotropium in Chronic Obstructive Pulmonary Disease (COPD), Int. J. of Pharm. Sci., 2026, Vol 4, Issue 11, 2793-2797. https://doi.org/10.5281/zenodo.24331927
10.5281/zenodo.24331927